MedTrace Logo

HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

NCT05864755 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-08-23

No results posted yet for this study

Summary

To evaluate the efficacy and safety of HAIC combined with Durvalumab, Tremelimumab and Bevacizumab as first-line therapy in Unresectable hepatocellular carcinoma

Conditions

  • Unrescetable Hepatocellular Carcinoma

Interventions

DRUG

HAIC+Durvalumab+Tremelimumab+Bevacizumab

Tremelimumab：300mg, only once in cycle 1.Durvalumab: 1500mg, iv,q3w Bevacizumab: 15mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-20
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05864755 on ClinicalTrials.gov